热门资讯> 正文

Oramed Pharmaceuticals GAAP每股收益为1.26美元

2025-11-17 22:14

Oramed制药(ORMP) 0
欧朋公司(OPRA) 0

Oramed Pharmaceuticals press release (ORMP): nine-month period 2025 GAAP EPS of $1.26.
Robust balance sheet growth: Total assets increased 42% from $155.3 million to $220.5 million year-over-year.
Operating expenses: R&D expenses decreased from $4.9 million to $4.4 million; G&A expenses increased from $4.3 million to $5.0 million.

More on Oramed Pharmaceuticals

Seeking Alpha’s Quant Rating on Oramed Pharmaceuticals
Historical earnings data for Oramed Pharmaceuticals
Financial information for Oramed Pharmaceuticals

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。